PharmaMar presents positive results from a Phase II study of PM1183 in Ewing’s sarcoma

0

(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing´s sarcoma at the Connective Tissue Oncology Society´s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November.

Leave A Reply

Your email address will not be published.